Navigation Links
Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
Date:3/29/2011

, after which it plans to conduct the necessary studies required to initiate clinical trials later this year.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novogen and Marshall Edwards Sign Asset Purchase Agreement
2. Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
3. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
4. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
5. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
6. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
7. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
8. Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
10. Reportlinker Adds Quantum Dots: Technologies and Global Markets
11. Neogen Reports 27% Increase in Quarterly Net Income
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 06, 2015 Park Systems , ... the only high vacuum AFM system in the market ... analysis semiconductor manufacturing. Park NX-Hivac is ideal for academic ... solutions in highly doped semiconductor processing where more highly ... The high vacuum scanning spreading resistance microscopy (SSRM) of ...
(Date:5/5/2015)... RURO, Inc., a leading LIMS, RFID and ... latest major content upgrade to its bestselling, Commercial Off-The-Shelf ... is a significant advancement of FreezerPro® system , ... while also simplifying , New FreezerPro® ... Download available immediately for free to “Gold” support ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 ... Life Science Animal Health, Jeffrey Schaffer, DVM, as ... “With over 15 years of experience in the ... a great addition to our veterinarian lead organization”. ... Officer, explains. “Dr. Schaffer will be responsible for ...
(Date:5/5/2015)... The Academy of Model Aeronautics is pleased to ... Gov. Mike Pence, has declared August 15, 2015, as ... Family Fest and aviation themed Motorcycle Rally in Muncie, ... Warrior Project. , National Model Aviation Day has been ... organization for model aviation—to celebrate the history of model ...
Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3RURO Releases version 7 of FreezerPro® software 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2State of Indiana proclaims August 15 as Model Aviation Day 2
... 15, 2012  OrbusNeich today announced that 12-month follow-up data ... outcomes involving the use of the company,s Combo Dual ... Liberte ® paclitaxel-eluting stent. The data were presented ... the Lukaskrankenhaus in Neuss, Germany, at EuroPCR 2012. ...
... DIEGO, May 15, 2012 Cardium Therapeutics (NYSE Amex: ... for the first quarter ended March 31, 2012, and ... In addition to the announcement of ... for 2012, which were outlined in the year-end report, ...
... May 15, 2012 Butamax™ Advanced Biofuels, LLC ... Trademark Office (USPTO) has granted Butamax Patent Number ... engineered pathway for producing isobutanol from recombinant microorganisms ... designed using advanced biotechnology to convert sugar to ...
Cached Biology Technology:OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 2OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 3OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up 4Cardium Presents First Quarter 2012 Financial Results and Recent Developments 2Cardium Presents First Quarter 2012 Financial Results and Recent Developments 3Cardium Presents First Quarter 2012 Financial Results and Recent Developments 4Cardium Presents First Quarter 2012 Financial Results and Recent Developments 5Cardium Presents First Quarter 2012 Financial Results and Recent Developments 6Cardium Presents First Quarter 2012 Financial Results and Recent Developments 7Cardium Presents First Quarter 2012 Financial Results and Recent Developments 8Cardium Presents First Quarter 2012 Financial Results and Recent Developments 9Cardium Presents First Quarter 2012 Financial Results and Recent Developments 10Cardium Presents First Quarter 2012 Financial Results and Recent Developments 11Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol 2
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 27, 2008) -- Using a breakthrough technology, researchers led by ... estrogen as a key player in about half of all ... aggressive form of the disease caused by a chromosomal translocation, ... "Fifty percent of prostate cancers harbor a common ...
... that a fundamental building block in the cells ... on a separate branch of the evolutionary tree--in ... at least 420 million years ago. ... the group that includes conifers, ginkgos and related ...
... 26 May 2008] Scientists at the Swedish medical university ... is much cheaper than those currently in use in ... it possible to map disease genes in large patient ... new treatments for a wide variety of diseases. ...
Cached Biology News:Estrogen helps drive distinct, aggressive form of prostate cancer 2Estrogen helps drive distinct, aggressive form of prostate cancer 3When plants 'think' alike 2New cheaper method for mapping disease genes 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Non-Protein Peroxidase Stabilizer , 1 L...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
... All MagCellect Ferrofluid products ... conjunction with R&D Systems MagCellect ... capacities, this neodymium iron boron ... 12 x 75 mm test ...
Biology Products: